ClinicalTrials.gg
RecruitingNCT07438964Updated Feb 27, 2026

Non-invasive Brain Stimulation in Multiple Sclerosis Fatigue

An interventional study of tDCS of dlPFC and Sham Stimulation of dlPFC in Multiple Sclerosis and Fatigue in Multiple Sclerosis, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Charite University, Berlin, Germany.

Planned enrollment
6th of 14
84 · median 53
Started
2026
the only one that year
No phase
10 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 19th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, or all of them as a file.
02

Study summary

The neurobiological basis of central fatigue in multiple sclerosis remained unclear so far. This study investigates reward-related brain mechanisms, inflammation, and their modulation by non-invasive brain stimulation using fMRI, proteomics, and clinical measures to improve future treatment of central fatigue in MS. In the study, persons suffering from relapsing-remitting MS (RRMS) with vs. without comorbid central fatigue will be included.

The study comprises five experimental visits conducted at Charité University Medicine on five consecutive days (i.e., V1 - V5) and two follow-up visits two (V6) and four (V7) weeks after V5. True or sham anodal transcranial Direct Current Stimulation (tDCS) is applied to the left dorsolateral prefrontal cortex (dlPFC) at the five visits V1 to V5. All primary and secondary outcomes are assessed at V1 and V5.

At V6 and V7, measures of central fatigue are additionally assessed via questionnaires which are send to and back from the patients via mail.

Participants of all groups will participate in all visits.

03

Conditions studied

  • Multiple Sclerosis
  • Fatigue in Multiple Sclerosis

Keywords

  • Transcranial direct current stimulation
  • Fatigue
  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women

    • 18 - 70 years
    • Established MS diagnosis (relapsing-remitting MS; RRMS) prior to study inclusion
    • Maximal EDSS of 4
    • Maximal disease duration 10 years
    • Existing health insurance
    • Stable or no treatment with disease modifying treatment (DMT) in last six months prior to study onset
    • Persons with RRMS and FSMC score ≥ 22 will be included in group "RRMS with fatigue"
    • Persons with RRMS and FSMC score \< 22 will be included in group "RRMS without fatigue"

Exclusion criteria

Exclusion Criteria:

    • MRI

      • Known endocrine, immunologic, psychiatric, and neurologic disease (other than RRMS and Major Depressive Diosorder)
      • Current treatment with pharmaceuticals affecting monoaminergic functioning such as Levodopa, Amantadin, Fluoxetin, Paroxetin or antipsychotics
      • Relapse or treatment with in last four weeks window prior to study onset
      • DMT other than B-cell depleting monoclonal antibodies or fumarates
      • Sleep disorder as assessed with Pittsburgh Sleep Quality Index
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
84 participants (estimated)

Study arms

  • Active comparator
    tDCS Stimulation of dlPFC

    Medical device: tDCS Stimulation over left dorsolateral prefrontal cortex (DLPFC) for 20 min daily over 5 consecutive days

    Device: tDCS of dlPFC

  • Sham comparator
    Sham Stimulation of dlPFC

    Medical device: Placebo Sham stimulation over left dorsolateral prefrontal cortex (dlPFC) for 20 min daily over 5 consecutive days

    Device: Sham Stimulation of dlPFC

Interventions

  • DevicetDCS of dlPFC

    Transcranial direct current stimulation over left dorsolateral prefrontal cortex (DLPFC) for 20 min daily over 5 consecutive days at 1200 uA

  • DeviceSham Stimulation of dlPFC

    Sham Stimulation of the dlPFC via tDCS device for 20 minutes on 5 consecutive days

06

What researchers measure

Primary outcomes

  1. Central fatigue

    Assessed with cognitive subscale of with Fatigue Scale for Motor and Cognitive Functions (FSMC): Minimum 20 points, maximum 100 points, higher values denoting worse outcome

    Time frame: At enrolment and 4 days, two weeks and four weeks after enrolment

  2. Neurobehavioral markers of effort discounting

    Measured in a functional MRI (fMRI) task

    Time frame: At enrolment and 4 days after enrolment

  3. Neurobehavioral markers of habit formation

    Measured in an fMRI task

    Time frame: At enrolment and 4 days after enrolment

  4. White matter integrity MRI measure

    Computed as voxel-wise quotients of T1-weighted and T2-weigted anatomical MRI brain scan parameters

    Time frame: At enrolment and 4 days after enrolment

  5. Brain age marker

    Inferred via machine learning from anatomical T1-weighted brain scan

    Time frame: At enrolment and 4 days after enrolment

  6. Whole-brain grey matter fraction

    Inferred from anatomical T1-weighted brain MRI scans

    Time frame: At enrolment and 4 days after enrolment

  7. Whole-brain volume of focal brain lesions

    Inferred from anatomical T2-weighted brain MRI scans

    Time frame: At enrolment and 4 days after enrolment

Secondary outcomes

  1. Change in concentration of inflammatory markers

    124 blood-derived inflammatory cytokine and chemokine markers determined via an inflammatory panel

    Time frame: At enrolment and 4 days after enrolment

  2. Change in cognitive performance

    Brief International Cognitive Assessment for MS (BICAMS)

    Time frame: At enrolment and 4 days after enrolment

  3. Complementary fatigue markers

    Fatigue Severity Scale (FSS), Minimum value 7, Maximum value 63, higher score denoting a worse outcome.

    Time frame: At enrolment, and 4 days, two and four weeks after enrolment

  4. Severity of depressive symptoms

    Beck Depression Inventory (BDI-II), Minimum value 0, Maximum value 63, higher values denoting worse outcome

    Time frame: At enrolment and 4 days after enrolment

  5. Sleep quality

    Pittsburgh Sleep Quality Index (PSQI), Minimum Score 0, Maximum Score 21, higher score denoting worse outcome

    Time frame: At enrolment and 4 days after enrolment

  6. Severity of anxiety symptoms

    Measured on the State-Trait Anxiety index-I (STAI-I), minimum score 20, maximum score 80, higher score denoting worse outcome

    Time frame: At enrolment and 4 days after enrolment

  7. Change in Fatigue severity

    Visual analogue scale of fatigue (VAS-F), minimum value 1, maximum value 10, higher score denoting worse outcome

    Time frame: At enrolment, and 1,2,3,4 days, two and four weeks after enrolment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification.

Supporting information: Study protocol

Time frame: Beginning three years after project end

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2028, 24 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartEst.
Mar 2, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jun 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07438964
Responsible party
Janina Behrens (Principal Investigator, Charite University, Berlin, Germany) — Principal investigator
First posted
Feb 27, 2026
Start date
Mar 2, 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Janina Dr. Behrens, Dr. med.
Contact
janina.behrens@charite.de
+49 30 7560921
Martin Dr. Weygandt, PhD
Contact
martin.weygandt@mdc-berlin.de
Chotima Dr. Böttcher, PhD
principal investigator · Max-Delbrück-Centrum Berlin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion